COVID-19-vaccinatie | LCI richtlijnen
Under S&D leadership, European Parliament calls for lifting of patents for Covid-19 vaccines to save lives | Socialists & Democrats
Belgian minister tweets EU's Covid vaccine price list to anger of manufacturers | Coronavirus | The Guardian
7,6 miljoen euro in de vuilnisbak? 400.000 Novavax-vaccins vervallen binnenkort, en niemand wil ze
Nuvaxovid alternatief voor mensen die niet tegen Covid-19 konden gevaccineerd worden | Zorgnet-Icuro
Preventive care - For a Healthy Belgium
The Effect of Maternal Immunisation During Pregnancy on Infant Vaccine Responses - EClinicalMedicine
Preventive care - For a Healthy Belgium
Why has France not yet eliminated measles? - VaccinesToday
Waar blijft CureVac, het vijfde vaccin dat België bestelde? | De Morgen
France measles outbreak: babies hit hardest - VaccinesToday
The Impact of 2-Dose Routine Measles, Mumps, Rubella, and Varicella Vaccination in France on the Epidemiology of Varicella and Zoster Using a Dynamic Model With an Empirical Contact Matrix - Clinical Therapeutics
Opening van het grootste Belgische vaccinatiecentrum op de Heizel | Gemeenschappelijke Gemeenschapscommissie
Vaccinations in Belgium: the Belgian vaccine schedule | Expatica
EU drug regulator reviewing woman's death in Belgium after getting J&J shot – EURACTIV.com
Coronavaccin veilig en werkzaam bij kinderen van 5 tot 11 jaar", maar lang niet zeker of we hen ook zullen vaccineren | VRT NWS: nieuws
Belgian regulators advise against giving AstraZeneca Covid vaccine to over-55s | Belgium | The Guardian
Vaccination | Coronavirus COVID-19
De situatie in België in 2016 - Vax Info
Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial - eBioMedicine
Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study - eBioMedicine
High number of hospitalisations and non-classical presentations: lessons learned from a measles outbreak in 2017, Belgium | Epidemiology & Infection | Cambridge Core
